ARQT

Nasdaq

Arcutis Biotherapeutics, Inc.

Latest disclosureSeptember 18, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 26 sales

Price by TradingView

Insider transactions 79

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. Sales: $456.21K by 2 insiders.

Showing the first 6 of 20 trades on this page.

Sale disclosed

Masaru Matsuda

See Remarks

Common Stock

Reported value: $91.85K
Reported price: $25.0009 / share

Sale disclosed

Howard G. Welgus

Director

Common Stock

Reported value: $114.37K
Reported price: $24.18 / share

Sale disclosed

Masaru Matsuda

See Remarks

Common Stock

Reported value: $249.99K
Reported price: $25.0261 / share

Sale disclosed

Terrie Curran

Director

Common Stock

Reported value: $279.03K
Reported price: $25.0294 / share

Sale disclosed

Terrie Curran

Director

Common Stock

Reported value: $677.1K
Reported price: $25.0294 / share

Sale disclosed

Terrie Curran

Director

Common Stock

Reported value: $27.91K
Reported price: $26.0376 / share

Sale disclosed

Patrick Burnett

See Remarks

Common Stock

Reported value: $45.82K
Reported price: $27.00 / share

Sale disclosed

Howard G. Welgus

Director

Common Stock

Reported value: $123.83K
Reported price: $26.1807 / share

Sale disclosed

Patrick Burnett

See Remarks

Common Stock

Reported value: $220.13K
Reported price: $26.5216 / share

Sale disclosed

Patrick Burnett

See Remarks

Common Stock

Reported value: $174.77K
Reported price: $26.0847 / share

Sale disclosed

Patrick Burnett

See Remarks

Common Stock

Reported value: $24.94K
Reported price: $26.1168 / share

Sale disclosed

Masaru Matsuda

See Remarks

Common Stock

Reported value: $32.12K
Reported price: $26.1168 / share

Sale disclosed

Todd Watanabe

See Remarks

Common Stock

Reported value: $114.26K
Reported price: $26.1168 / share

Sale disclosed

Howard G. Welgus

Director

Common Stock

Reported value: $127.28K
Reported price: $26.91 / share

Sale disclosed

Sue-Jean Lin

Director

Common Stock

Reported value: $120.59K
Reported price: $24.3807 / share

Sale disclosed

Howard G. Welgus

Director

Common Stock

Reported value: $99.98K
Reported price: $24.4093 / share

Sale disclosed

Howard G. Welgus

Director

Common Stock

Reported value: $16.3K
Reported price: $25.67 / share

Sale disclosed

Latha Vairavan

SVP Chief Financial Officer

Common Stock

Reported value: $9.16K
Reported price: $21.05 / share

Sale disclosed

Patrick Burnett

See Remarks

Common Stock

Reported value: $4.67K
Reported price: $21.05 / share

Sale disclosed

Masaru Matsuda

See Remarks

Common Stock

Reported value: $171.54K
Reported price: $23.2696 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
See Remarks	Common StockSale10b5-1	3,674$25.00 / share	$91.85K	Sep 16Filed Sep 18 · 2d later	SEC filing
Director	Common StockSale10b5-1	4,730$24.18 / share	$114.37K	Sep 15Filed Sep 17 · 2d later	SEC filing
See Remarks	Common StockSale10b5-1	9,989$25.03 / share	$249.99K	Sep 8Filed Sep 10 · 2d later	SEC filing
Director	Common StockSale2 trades	38,200avg $25.03 / share	$956.12K	Aug 27Filed Aug 28 · 1d later	2 filings 11,148 @ $25.03 · $279.03KSEC filing 27,052 @ $25.03 · $677.1KSEC filing
Director	Common StockSale	1,072$26.04 / share	$27.91K	Aug 20Filed Aug 24 · 4d later	SEC filing
See Remarks	Common StockSale	1,697$27.00 / share	$45.82K	Aug 19Filed Aug 21 · 2d later	SEC filing
Director	Common StockSale10b5-1	4,730$26.18 / share	$123.83K	Aug 17Filed Aug 19 · 2d later	SEC filing
See Remarks	Common StockSale	8,300$26.52 / share	$220.13K	Aug 11Filed Aug 13 · 2d later	SEC filing
See Remarks	Common StockSale	6,700$26.08 / share	$174.77K	Aug 12Filed Aug 13 · 1d later	SEC filing
See Remarks	Common StockSale10b5-1	955$26.12 / share	$24.94K	Aug 3Filed Aug 5 · 2d later	SEC filing
See Remarks	Common StockSale10b5-1	1,230$26.12 / share	$32.12K	Aug 3Filed Aug 5 · 2d later	SEC filing
See Remarks	Common StockSale10b5-1	4,375$26.12 / share	$114.26K	Aug 3Filed Aug 5 · 2d later	SEC filing
Director	Common StockSale10b5-1	4,730$26.91 / share	$127.28K	Jul 15Filed Jul 17 · 2d later	SEC filing
Director	Common StockSale10b5-1	4,946$24.38 / share	$120.59K	Jun 15Filed Jun 17 · 2d later	SEC filing
Director	Common StockSale10b5-1	4,096$24.41 / share	$99.98K	Jun 15Filed Jun 17 · 2d later	SEC filing
Director	Common StockSale10b5-1	635$25.67 / share	$16.3K	Jun 17Filed Jun 17 · 0d later	SEC filing
SVP Chief Financial Officer	Common StockSale10b5-1	435$21.05 / share	$9.16K	May 11Filed May 13 · 2d later	SEC filing
See Remarks	Common StockSale10b5-1	222$21.05 / share	$4.67K	May 11Filed May 13 · 2d later	SEC filing
See Remarks	Common StockSale10b5-1	7,372$23.27 / share	$171.54K	May 4Filed May 6 · 2d later	SEC filing

Showing the latest 20 of 26 trades. Show all 26 trades

Congress transactions 3

All Congress filings

Purchase disclosed

Arcutis Biotherapeutics, Inc. - Common stock (ARQT) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 29, 2026

Purchase disclosed

Arcutis Biotherapeutics, Inc. - Common stock (ARQT) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 3, 2026

Partial sale disclosed

Arcutis Biotherapeutics, Inc. - Common stock (ARQT) · Stock

The filing reports a partial sale for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 11, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001787306
Latest public acceptance: Sep 18, 2026, 08:17 PM UTC
Score calculated: Oct 8, 2026, 12:09 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

See Remarks

Common StockSale10b5-1

3,674$25.00 / share

$91.85K

Sep 16Filed Sep 18 · 2d later